Precision Neuroscience

Precision Neuroscience is a neurotechnology company developing a brain-computer interface (BCI) system called the Layer seven Cortical Interface. This implant comprises 1,024 tiny electrodes spanning an area of one square centimeter, embedded in a flexible film that conforms to the brain's surface. The film, one-fifth the thickness of a human hair, is designed for implantation and removal by neurosurgeons without damaging brain tissue. Precision Neuroscience aims to map a large area of the brain's surface at resolutions higher than typical neurosurgical procedures.

The Layer seven Cortical Interface is engineered to read, record, and map electrical activity from the brain's surface, providing an unprecedented level of detail. It has the potential to restore function to individuals suffering from neurological conditions such as speech deficits, paralysis, and epilepsy. In April and May 2023, the company successfully completed the first-in-human pilot clinical study, temporarily implanting the device in patients undergoing brain tumor resection surgeries at West Virginia University's Rockefeller Neuroscience Institute.

Precision Neuroscience seeks to leverage the high-resolution neural data collected by its arrays to advance our understanding of how the brain coordinates complex behaviors. The company expects to file for FDA clearance for use in diagnostic electrophysiology mapping procedures lasting up to 30 days in the coming months. As of October 2023, Precision Neuroscience's BCI technology has been awarded Breakthrough Device designation by the FDA, expediting the review process.

In October 2023, Precision Neuroscience acquired a microelectromechanical systems (MEMS) foundry outside Dallas, Texas, through its subsidiary Precision BioMEMS Corporation. This acquisition brings the supply chain in-house, enabling greater quality control and the ability to iterate rapidly on future versions of the Layer seven Cortical Interface.